Johanna Friedl-Naderer, Chief Commercial Officer at Dyne Therapeutics ($DYN), sold shares on the open market five times over the past year, totaling about $21,000. Her most recent sale occurred on March 5, 2026. These transactions rank 11,014th among 11,678 insiders by sale value, well below the average of 8.6 million per insider across 6.37 transactions. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | S | Common Stock | 148 | $14.90 | 154,581.0000 | 142,824,687 | 0.10% | 0.00% |
| Feb. 12, 2026 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | A | Stock option (right to buy) | 90000 | $0.00 | 90,000.0000 | 142,824,687 | 9999.99% | 0.06% |
| Feb. 12, 2026 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | A | Common Stock | 60000 | $0.00 | 154,729.0000 | 142,824,687 | 63.34% | 0.04% |
| Dec. 5, 2025 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | S | Common Stock | 144 | $20.72 | 94,729.0000 | 142,824,687 | 0.15% | 0.00% |
| Sept. 5, 2025 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | S | Common Stock | 144 | $13.41 | 94,873.0000 | 113,121,357 | 0.15% | 0.00% |
| Sept. 4, 2025 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | S | Common Stock | 894 | $13.27 | 95,017.0000 | 113,121,357 | 0.93% | 0.00% |
| July 16, 2025 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | A | Stock option (right to buy) | 51255 | $0.00 | 51,255.0000 | 113,121,357 | 9999.99% | 0.05% |
| June 5, 2025 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | S | Common Stock | 146 | $13.35 | 95,911.0000 | 113,121,357 | 0.15% | 0.00% |
| March 13, 2025 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | S | Common Stock | 143 | $12.12 | 96,057.0000 | 113,121,357 | 0.15% | 0.00% |
| Dec. 4, 2024 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | A | Stock option (right to buy) | 60300 | $0.00 | 60,300.0000 | 0 | 9999.99% | 0.00% |
| Dec. 4, 2024 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | A | Common Stock | 37800 | $0.00 | 96,200.0000 | 0 | 64.73% | 0.00% |
| Sept. 3, 2024 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | A | Stock Option (Right to Buy) | 185300 | $0.00 | 185,300.0000 | 0 | 9999.99% | 0.00% |
| Sept. 3, 2024 | Dyne Therapeutics, Inc. | $DYN | Friedl-Naderer Johanna | Chief Commercial Officer | A | Common Stock | 58400 | $0.00 | 58,400.0000 | 0 | 9999.99% | 0.00% |
| March 3, 2023 | Vir Biotechnology, Inc. | $VIR | Friedl-Naderer Johanna | EVP & Chief Operating Officer | S | Common Stock | 1482 | $22.82 | 148,518.0000 | 0 | 0.99% | 0.00% |
| Feb. 22, 2023 | Vir Biotechnology, Inc. | $VIR | Friedl-Naderer Johanna | EVP & Chief Operating Officer | A | Common Stock | 60000 | $0.00 | 150,000.0000 | 0 | 66.67% | 0.00% |
| Feb. 22, 2023 | Vir Biotechnology, Inc. | $VIR | Friedl-Naderer Johanna | EVP & Chief Operating Officer | A | Stock Option (Right to Buy) | 70000 | $0.00 | 70,000.0000 | 0 | 9999.99% | 0.00% |